Episode 37

full
Published on:

21st Dec 2025

Beyond Chemical Imbalance: New Frontiers in Psychiatry with Dr. Theodore Henderson - #37

Beyond Chemical Imbalance: New Frontiers in Psychiatry with Dr. Theodore Henderson - #37

In this episode of the Neurostimulation Podcast, host Mike welcomes Dr. Theodore Henderson, a pioneering psychiatrist and neuroscientist whose work is reshaping the field of mental health. Dr. Henderson challenges the traditional "chemical imbalance" model of psychiatric disorders, advocating for a more nuanced understanding rooted in neuroimaging, neuroplasticity, and the biology of inflammation.

Key Topics Discussed:

  1. Dr. Henderson’s Journey: From a background in neurobiology and radiology to psychiatry, and how questioning the status quo led him to innovative treatments.
  2. Moving Beyond Chemical Imbalance: Why the serotonin hypothesis is outdated, and how new research points to neuroplasticity and mitochondrial health as central to mental wellness.
  3. Neuroimaging and Diagnosis: The role of SPECT scans in identifying brain dysfunction, traumatic brain injury, and differentiating between psychiatric conditions.
  4. Infrared Light Therapy (Photobiomodulation): How Dr. Henderson’s research has advanced the use of infrared light to stimulate brain repair, neuroplasticity, and recovery from conditions like depression, chronic fatigue syndrome, and traumatic brain injury.
  5. Ketamine and Synergistic Treatments: The science behind ketamine’s effects on neuroplasticity, and how combining it with infrared therapy can yield powerful results.
  6. Neuroinflammation and Viral Triggers: Insights into how chronic fatigue, depression, and even some cases of Parkinson’s and Alzheimer’s may be linked to viral infections and neuroinflammation.
  7. Long COVID: Dr. Henderson’s approach to treating long COVID symptoms, including fatigue and brain fog, with antiviral therapies and infrared light.
  8. Personalized Psychiatry: The importance of moving away from a “cookbook” approach to mental health, and embracing individualized, biomarker-driven diagnostics and treatments.
  9. Future Directions: The promise of next-generation transcranial magnetic stimulation (TMS), ongoing research collaborations, and the need for broader access to innovative therapies.

Actionable Insights:

  1. Clinicians: Consider neuroinflammatory and viral contributions to psychiatric symptoms; basic blood tests and antibody panels can be informative.
  2. Patients: There is hope beyond standard medications—emerging therapies may offer new avenues for recovery.

Resources:

  1. Dr. Henderson’s book: Brighter Days Ahead (link in show notes)
  2. Dr. Henderson’s clinic and contact information (link in show notes)

Connect with Dr. Henderson:

  1. https://neuro-luminance.com/about/
  2. https://neuro-luminance.com/brighter-days-ahead/

If you’re interested in the future of mental health treatment, from infrared laser therapy to the role of neuroinflammation, this episode is essential listening.

Transcript
Speaker:

Welcome back to the

Neurostimulation podcast.

2

:

Today I'm joined by Dr.

3

:

Theodore Henderson, a trailblazing

psychiatrist, and neuroscientist whose

4

:

work is redefining how we understand

and treat brain disorders from

5

:

depression to traumatic brain injury,

long COVID to chronic fatigue syndrome.

6

:

Dr.

7

:

Henderson has pioneered approaches

that challenge the outdated

8

:

chemical imbalance model.

9

:

His new book Brighter Days Ahead

offers hope grounded in neuroimaging,

10

:

infrared light therapy, and ketamine.

11

:

In this episode, we're gonna

dive into revolutionary

12

:

treatments, neurobiology, and Dr.

13

:

Henderson's own personal story

that fuels his mission to

14

:

change lives and change minds.

15

:

Dr.

16

:

Henderson, thanks for joining us today.

17

:

Thank you for having me, Michael.

18

:

So maybe we can start

with the big picture.

19

:

I was wondering perhaps you can introduce

yourself to the audience a little, tell

20

:

us about your background and then maybe

help us to understand how do you see the

21

:

field of psychiatry evolving away from the

legacy chemical imbalance type of model?

22

:

All right.

23

:

Yeah.

24

:

I, I think a childhood of adversity taught

me to be suspicious of the status quo.

25

:

And then I read Thomas Kuhn's

The Structure of Scientific

26

:

Revolutions in college.

27

:

It literally became my Bible.

28

:

And so every situation, every paradigm

I looked at, I was suspicious of,

29

:

and I questioned and I challenged it.

30

:

That served me well as a graduate

student and getting my PhD and served

31

:

me relatively well as a medical

student, although, the hierarchy

32

:

of medicine expects you to be the

obedient servant in in residency.

33

:

The, so I, I took all my

background in neurobiology and

34

:

went into radiology initially.

35

:

And spent about a year and a half

before I just couldn't stand it

36

:

anymore and switched to psychiatry

and never regretted that switch.

37

:

I think psychiatry allows me to really

make a difference in the world and really

38

:

help people, which is always been my goal.

39

:

The neuroimaging came back though

because I got involved in SPECT brain

40

:

imaging which is a functional brain

scan that shows you what's working

41

:

and what's not working in the brain.

42

:

And in that role I kept having to

tell people, look, the scan shows

43

:

you have a traumatic brain injury.

44

:

We've got nothing to help you.

45

:

Sorry, have a nice life.

46

:

That was very frustrating to me

as a clinician and as a person.

47

:

So when the opportunity came to get

involved in photobiomodulation, I

48

:

leaped at the chance, but the very

first thing I did was say, okay, we

49

:

gotta make this rigorously scientific.

50

:

And that's how I arrived at this point of

using photobiomodulation that is infrared

51

:

light as a treatment for the brain.

52

:

And thinking about all, neurological

and psychiatric disorders is

53

:

really being about insufficient

neuroplasticity and insufficient

54

:

mitochondrial and neuronal health.

55

:

That's probably enough.

56

:

Oh yeah.

57

:

No, I think that's a fantastic

introduction and it's so interesting

58

:

because I think we're at an exciting

time now in the field because of, as

59

:

you say, many different multimodal

kinds of approaches to management

60

:

are almost by definition having to

become more available for people.

61

:

Other reasons because legacy treatments,

particularly medications, are just

62

:

disappointing for so many people.

63

:

And other kinds of

options are sorely needed.

64

:

Yeah, I'm, I'm curious.

65

:

I think it's really interesting to hear

and perhaps, we can spend quite a bit

66

:

of time talking about those particular.

67

:

Kind of technologies and treatments

that you've just referred to, but I was

68

:

also interested in what you've written

about and have content on in terms of

69

:

depression and associated conditions,

like perhaps chronic fatigue syndrome

70

:

as neuroinflammatory conditions.

71

:

Perhaps maybe you could help

us to understand your thoughts

72

:

around that kind of thing as well.

73

:

Yeah.

74

:

That's a really interesting story.

75

:

Thank you for asking about that.

76

:

It, that really again, came

from this work in neuroimaging.

77

:

I have patients who are coming and

saying, they think they had a stroke.

78

:

And a stroke looks very

characteristic on a brain scan.

79

:

It's a.

80

:

The vascular territory of the

involved artery is shut down,

81

:

and I wasn't seeing that at all.

82

:

In fact, what I was seeing was diffuse,

patchy dysfunction throughout the

83

:

entire brain, and that raises a question

of, okay, this is something systemic.

84

:

This is' localized.

85

:

This is involving the whole brain.

86

:

In fact, probably the whole body.

87

:

So that led me to ask

the patients questions.

88

:

And what came out was a a downward

trajectory of more and more fatigue and

89

:

brain fog and concentration problems

and memory problems and errors at work.

90

:

And that very much sounded

like chronic fatigue syndrome.

91

:

Now, I had.

92

:

I already had some brushes with

the interaction of certain viruses,

93

:

in particular Epstein-Barr virus,

which is herpes four and herpes six

94

:

with which is just called herpes

six in brain dysfunction in areas

95

:

of autism and things like that.

96

:

In my neuroimaging work.

97

:

So as a clinician, then I started

researching what was out there

98

:

and discovered a Martin Lerner's

pioneering work on treating chronic

99

:

fatigue syndrome with antivirals

directed against those herpes viruses.

100

:

So I started treating patients,

and here's the weird thing, not

101

:

only did they, recover from the

fatigue and the brain fog, but

102

:

their anxiety disorders went away.

103

:

I started having patients who came

in with, saying, I'm depressed, doc.

104

:

And okay what makes you

think you're depressed?

105

:

I'm tired all the time.

106

:

Oh, okay.

107

:

So they had been diagnosed as

depression and put on SSRIs when

108

:

in fact they had a viral infection.

109

:

So I started curing depression by

treating them with an antiviral.

110

:

So that sort of.

111

:

Shift opened my eyes to, not

being stuck in a paradigm.

112

:

If they say they're depressed or

somebody's told them they're depressed,

113

:

maybe you need to ask more questions.

114

:

And the fascinating thing is, I'm

now treated, four or 500 patients for

115

:

chronic fatigue syndrome, and all sorts

of interesting things have happened.

116

:

Their seizure disorders have gone away.

117

:

That one always blows

away, neurologists away.

118

:

I have patients who were diagnosed with

Parkinson's disease and after treating

119

:

them their Parkinson's symptoms went away.

120

:

And literally they go back

to the neurologist and the

121

:

neurologist says I guess you

didn't have Parkinson's after all.

122

:

So it's been remarkable to see, the

number of different disorders by symptom

123

:

phenotype that turn out to actually

be the results of viral infections.

124

:

Alzheimer's, again is a

great example of this.

125

:

We could spend an hour

talking about Alzheimer's.

126

:

Yeah, absolutely.

127

:

Yeah.

128

:

In particular with some recent

evidence that's really casting doubt

129

:

on a lot of the underlying concepts

around pathophysiology of Alzheimer's.

130

:

But I think just the fact that you

mentioned coon's structure of scientific

131

:

revolutions at the beginning is really

interesting because I think part of

132

:

what many psychiatrists struggle with,

particularly, mid or later career

133

:

psychiatrist, is, working in the system

and becoming frustrated with, and

134

:

maybe having some more insight into

how, the pharmac industrial regulatory

135

:

kind of capture is part of what kind

of guides, training and then guides

136

:

early practice and you feel a bit.

137

:

Because clinical practice guidelines

are also part of, in a way, part of

138

:

that capture and then what your peers

are doing is part of that capture.

139

:

And you feel like if you want to

maybe explore ideas that are out of

140

:

the box there's so many different

barriers that get in the way of that,

141

:

and that the root of least resistance

is just to go along to get along.

142

:

And that ends up causing

patients to, be on four or five.

143

:

Different psychotropic medications at

the end of the day because, and they

144

:

don't have, it's really sad in many

cases because they just don't have

145

:

the opportunity to see someone like

you who thinks out of the box and

146

:

might diagnose them with more of an

inflammatory condition that could in

147

:

fact be curative as you're describing.

148

:

Yeah.

149

:

So it's very much that, that

paradigm and the chemical imbalance

150

:

theory, that depression is about

serotonin that's been disproven.

151

:

Four meta-analyses.

152

:

The latest was published about two

years ago that prove that serotonin

153

:

has nothing to do with mood.

154

:

The fact that Prozac increases

serotonin, which it does in about

155

:

an hour is a happy accident.

156

:

Prozac really does as an antidepressant

is very poorly, very weekly.

157

:

If you're lucky and Saturn happens to

be in retrograde and Capricorn, that you

158

:

will get an antidepressant benefit because

it very weekly turns on neuroplasticity.

159

:

Yeah, that's interesting.

160

:

And then you add in factors like placebo

or expectation effects, and then, those

161

:

more recent comparison meta-analyses and

RCTs are showing that often they don't

162

:

separate out much from placebo effects.

163

:

So there you go.

164

:

Yes, exactly.

165

:

Exactly.

166

:

Yeah.

167

:

So maybe I'm interested then, so could

you help us understand a bit about

168

:

different technologies that people may not

be familiar with that could potentially

169

:

help with conditions like depression?

170

:

In particular, I'm wondering

about this infrared laser therapy,

171

:

which sounds very interesting.

172

:

Yes.

173

:

So the infrared photobiomodulation story

goes back actually to the Soviet Union.

174

:

So that's about 50 years ago.

175

:

NASA played around with it for a

little bit and found that they could

176

:

speed the wound healing of astronauts.

177

:

So the astronauts had an infrared

device up on their vehicles,

178

:

I guess is the best word.

179

:

But Harvard and a few other places,

uniform Services Hospital, and university

180

:

of Sydney really got invested in

understanding photobiomodulation.

181

:

So really key work came out of

Harvard that showed that if you in,

182

:

take a hundred mice, whack-a-mole in

the head with a machine that gives

183

:

'em all the same traumatic brain

injury, treat 50 with infrared light.

184

:

Those 50 that were treated get better.

185

:

The lesion is smaller in the brain.

186

:

There's evidence that BDNF brain

derived neurotrophic factors turned on.

187

:

This is the driver of

neuroplasticity in the adult brain.

188

:

And so there's evidence of increased

synapses, increased dendrites, and

189

:

those little mice that had a brain

injury or up running around, like

190

:

nothing ever happened to them.

191

:

So that pioneering work and the same

kind of work was done in stroke.

192

:

Showed that infrared light turns

on a system and that system

193

:

involves first the mitochondria.

194

:

So certain wavelengths of infrared

light, if it can get through the

195

:

scalp and skull and reach the brain

cell, activates the mitochondria.

196

:

I could go into all the science of

that, but let's just leave it at that.

197

:

The mitochondria in turn produce

more energy, but they also send

198

:

signals down to the chromosomes

saying, turn on these genes.

199

:

And so one of those genes is brain derived

neurotrophic factor, but there are several

200

:

growth factors turned on depending on the

cell type as well as anti-inflammatory.

201

:

Factors.

202

:

So the infrared light is

actually activating brain cell

203

:

repair and neuroplasticity.

204

:

Now the problem is that the

skull of a mouse is about the

205

:

thickness of six sheets of paper.

206

:

So a half watt LED can

shine infrared light.

207

:

Through that, we have much thicker skulls,

mine, thicker than most, and then our

208

:

scalp is a good six millimeters thick.

209

:

And a half lot LED doesn't even penetrate

one millimeter through human skin.

210

:

So an LED is not gonna get

through the scalp and it and the

211

:

skull and get into the brain.

212

:

That's the problem with all these

LED devices that you can buy.

213

:

You can go and spend $4,000, or you

can spend $27 on Amazon and get an

214

:

LED infrared light device that you

can stick on your head and pretend

215

:

that you're treating your brain.

216

:

And I say pretend 'cause it's not

getting through the scalp and skull.

217

:

Now there is a skin effect.

218

:

Something in the skin gets activated,

which has benefit to the entire body.

219

:

Treating the skin will speed,

wound healing throughout the body

220

:

helps the brain a little bit.

221

:

But the problem is, it's transient.

222

:

If you don't keep doing those LED

treatments every day, as soon as

223

:

you stop, the benefit goes away.

224

:

Now contrast that with what we do.

225

:

We went into the lab and figured out how

to get through the scalp and skull and

226

:

three centimeters into the brain safely,

and deliver the right amount of energy to

227

:

those neurons to turn on the mitochondria.

228

:

That took us about a year and a half in

the research lab involving sheep heads,

229

:

cadaver heads, living tissue, to sort

out those penetration parameters, and we

230

:

applied those parameters then to people.

231

:

And we have the, we first were treating

traumatic brain injury, so we had brain

232

:

scans on them before and after treatment.

233

:

And the changes were dramatic and not

only what you could see on the scan,

234

:

but in these people's lives, right?

235

:

Yeah.

236

:

Yeah.

237

:

That's amazing.

238

:

It's really, yeah.

239

:

Very interesting.

240

:

And this idea about the

neuroplasticity in the BDNF.

241

:

Induced therapeutic changes.

242

:

It's really interesting how there's

a confluence that seems to be

243

:

a unifying factor that's common

to the infrared laser therapy.

244

:

The ketamine, as you say, to a small

extent, SSRIs, maybe can you help

245

:

us understand, for example, like

with ketamine then as another option

246

:

to improve neuroplasticity and how

that seems to really correlate.

247

:

Not only correlate, but cause

improvements in conditions like

248

:

the depression and chronic fatigue.

249

:

Yeah.

250

:

Great question.

251

:

Thank you.

252

:

So ketamine activates BDNF by a separate

mechanism and it does very powerful

253

:

and through a series of molecular

steps, it actually turns on both

254

:

ketamine and the receptor for ketamine.

255

:

So there's more stuff and

more receptors for the stuff.

256

:

So that.

257

:

Boost neuroplasticity.

258

:

Now, one of the things that I

recognized pretty early on was

259

:

what if we put the two together?

260

:

Infrared light turns on BDNF by

a mitochondrial mechanism, and

261

:

ketamine turns it on by a different

mechanism through the NMDA receptor.

262

:

And in fact, you get synergy, you get

one plus one equals three, not two.

263

:

And in fact, we patented that.

264

:

Synergistic combination and in

doing that work, for example,

265

:

I'll just give you one example.

266

:

It's impossible to do the study where

treat someone with infrared light.

267

:

You go back in time, you treat them

with ketamine, you go back in time,

268

:

and then you treat them with both and

see, which you can't do that right

269

:

time machines only have one chair.

270

:

The.

271

:

Best analogy I can give you is that,

some of the patients that we treat

272

:

with both ketamine and infrared

light, their brain scan showed really

273

:

robust improvement in brain functions.

274

:

Our depression patients who were

severely depressed, and we combine

275

:

ketamine with infrared light therapy.

276

:

Just, I had a psychiatrist call

me up and said, what the blankety

277

:

blanket did you do to this lady?

278

:

She looks fantastic.

279

:

So it's a very robust change.

280

:

There are other modalities that

may have that same synergy.

281

:

Yeah, exactly.

282

:

And I think before we

started, you have mentioned.

283

:

Neuromodulation techniques, like the

transcranial magnetic stimulation.

284

:

And so I guess that would be an example

of some of those other technologies

285

:

yet that I suppose could continue

to act even more synergistically.

286

:

And it's interesting.

287

:

Because it strikes me that what

we're talking about really leads

288

:

to discussion as to how all of this

is creating a sorely needed kind of

289

:

environment where there's more of a

personalized approach to improving.

290

:

Mental health as opposed to the cookbook

approach that is, like I said before, has

291

:

disappointed so many people for so long.

292

:

That's a great point.

293

:

That's a great point.

294

:

Yeah.

295

:

The neuroimaging work that I've done

using functional brain scans or spec

296

:

scans it's been frustrating because

number one, science, psychiatry, and

297

:

neurologist just completely rejects.

298

:

SPEC scans.

299

:

It's been a fight and I actually wrote an

article with Dan Pave about two years ago

300

:

called The Legacy of the TAs and Report.

301

:

And the Tasman report was Neurology's

initial assessment of spec scans

302

:

25 years ago in which they said

all these things are useless.

303

:

The spec scans of 25 years

ago look like a RAR shock.

304

:

They look like an ink block.

305

:

They didn't look like a brain scan.

306

:

And now we have brain scans.

307

:

I can see details, I can see the

Klaus Strumm, I can see the putamen.

308

:

I can see the, all the little brain

structures I can see in a spec scan now

309

:

with the quality scans that we have.

310

:

And so you would think we'd be using

those in psychiatry because it helps

311

:

us to craft our treatment better.

312

:

No, not at all.

313

:

No.

314

:

Yeah, it's unfortunate, and I mean

it, I hate to sound conspiratorial,

315

:

but one, one, there's really hardly

any other conclusions when you

316

:

think about things like, why are

there such a dearth of biomarker

317

:

driven diagnostics in psychiatry?

318

:

Even something as.

319

:

As traditional, or some might say outdated

as the dexamethasone suppression test.

320

:

I remember mentors when I was in

training who were very smart people

321

:

who said that actually the DST

is quite a reasonable biomarker

322

:

diagnostic to add into the mix with.

323

:

Any kind of clinical diagnosis of a major

depressive episode, yet we don't use it.

324

:

And I think, I wonder if a lot of that

is just because again that there's

325

:

capture of the journals with the

pharmacoeconomic complex and the drug

326

:

companies aren't really interested

in having tests available that might

327

:

rule out depression and decrease

their, the number of people that might

328

:

be candidates for the treatments.

329

:

Yeah.

330

:

And bipolar one most often presents

initially with a depressive episode,

331

:

and the dexamethasone suppression test

would differentiate bipolar one from.

332

:

Major depressive disorder from unipolar

depression and prevent, maybe ever a

333

:

manic episode or you start treating

the bipolar disorder appropriately.

334

:

Same thing with brain spec scans.

335

:

About three years ago I published

with colleagues in Mary McClain and

336

:

a few others in Canada a series A,

a family who have bipolar disorder,

337

:

and they all got variant spec scans

and their brains are identical.

338

:

Absolutely identical.

339

:

They all have the same bipolar marker

features of increased asymmetrical

340

:

thalamic activity and asymmetrical,

increased cortical activity.

341

:

If we did a spec scan on unipolar

depression, then yeah, we would

342

:

pick up those bipolar cases before

they became, severely manic.

343

:

And, the savings in, the

economics just for the.

344

:

For the patient, not losing their

job with a manic episode, having

345

:

a worse course because they were

put on an antidepressant initially.

346

:

All of those things could be

prevented if we use biomarkers.

347

:

Yeah.

348

:

And spec is relatively available.

349

:

Even up here in Canada where, we have our

default I'm a little bit embarrassed to

350

:

say, our default for neuroimaging in on

the geriatric side where I'm spending most

351

:

of my time is still cranial CT scanning.

352

:

So even in our environment,

SPECT is relatively available.

353

:

And as again, in the geriatric

population to help differentiate.

354

:

Certain kinds of dementias, it

can be obviously quite helpful.

355

:

But we don't really think, I don't have

a large, younger or middle age adult

356

:

practice, but I think with colleagues,

I don't think many of them would ever

357

:

think about ordering a spec scan, but I

can see why there would be a lot of value

358

:

in that on the diagnostic side for sure.

359

:

Yeah.

360

:

Yeah.

361

:

And we could talk about Alzheimer's

and the Alzheimer's imaging

362

:

and, spective is more valuable

than say even a amyloid scan.

363

:

So again, you're right.

364

:

That's this engine that drives

things and nuclear medicine and

365

:

radiologists wanna do amyloid scans.

366

:

Yeah.

367

:

Yeah, it's interesting.

368

:

And I think, yeah, even more

interesting because of all the recent

369

:

concern that's coming out regarding

the potential that the whole amyloid

370

:

hypothesis for Alzheimer's might be.

371

:

Somewhat or perhaps

completely off the mark.

372

:

So what does that mean

for the whole approach?

373

:

Yeah, it's really interesting.

374

:

How about the long COVID syndrome?

375

:

Everyone you know is still concerned

about the legacy of COVID, obviously.

376

:

It was a huge, a very

impactful time for everyone.

377

:

Very disruptive for all kinds

of reasons and many folks are

378

:

left with this long COVID.

379

:

So I really don't know too much about

it, but it strikes me as interesting

380

:

in terms of the potential overlap with.

381

:

Something like chronic fatigue syndrome

and the neuroinflammatory component.

382

:

Do you mind helping us to understand

a little bit more about your work with

383

:

long COVID patients and how that ties

in with what we've been talking about?

384

:

I'd be happy to.

385

:

I just gave a presentation at the

World Brain Mapping Conference

386

:

in Los Angeles a few months ago,

and so this is fresh in my head.

387

:

The estimates are that about

30% of people who got COVID will

388

:

develop long COVID symptoms.

389

:

And long COVID symptoms are

fatigue, brain fog memory problems,

390

:

sometimes neurological symptoms

like ticks or tremors and also

391

:

gastrointestinal symptoms.

392

:

And then a lot of patients will

have persistent pulmonary symptoms,

393

:

shortness of breath, et cetera.

394

:

The theory is about COVID along

COVID, excuse me, are that number

395

:

one, maybe there's fragments of the

spike protein left over floating

396

:

around in the brain or the lungs.

397

:

Another theory is that there are

micro clots throughout the tissues.

398

:

I think that.

399

:

Is less likely.

400

:

But the most prominent theories

and the strongest theories are

401

:

number one, that there's persistent

inflammation in the tissues.

402

:

In fact, I've had three of my own

psychiatry patients who went to the

403

:

local pulmonary hospital and had lung

biopsies 'cause of their shortness

404

:

of breath and chest pain, and they

were told, oh, we found inflammation.

405

:

We don't know what it is, and we

don't know what to do about it.

406

:

That's how big inflammation

is a part of this.

407

:

So inflammation in the brain as well.

408

:

The second prominent theory

is that long COVID, because of

409

:

the cytokine storm, induces a

reactivation of latent infections

410

:

such as Epstein-Barr or Herpes six.

411

:

Now not everybody has,

or herpes six despite.

412

:

Medicines claim that's the case.

413

:

It's really in my hands.

414

:

It's about 60% of patients that I

have tested have Epstein-Barr and

415

:

about 55 to 58% have herpes six.

416

:

The third theory is there's reactivation

of latent bacterial infections

417

:

such as Lyme disease, Bartonella.

418

:

In treating these patients, number

one, I always go looking for the

419

:

Epstein-Barr evidence and if that's

there, I'm treating them with antivirals.

420

:

But, we're typically treating

the patients with infrared light

421

:

and around about treatment 10

their fatigue begins to improve.

422

:

And around about 1415, their cognitive

function is back to baseline.

423

:

I'll give you just one example.

424

:

So a dentist came up from Florida.

425

:

And he had been sidelined by the

fatigue and the brain fog, and he

426

:

had developed a tremor, not good

for a dentist to have a tremor.

427

:

And he had tried everything.

428

:

He had tried hyperbarics, he

had tried various infusions.

429

:

He had tried ozone therapy.

430

:

So he came to us pretty desperate

and having spent a ton of money on

431

:

all these other failed therapies.

432

:

He had 20 treatments,

roundabout treatment.

433

:

14.

434

:

He pulls me aside and

says, doc, this is weird.

435

:

I've taken Vyvanse a

stimulant my whole life.

436

:

'cause I have a DHD and

now it makes me jittery.

437

:

So I stopped taking it.

438

:

And Doc, I can concentrate just.

439

:

And so he, not only did his fatigue

go away, his mental clarity came back.

440

:

His energy, was through the roof.

441

:

He was doing fantastic.

442

:

His tremor gone and he

no longer had a DHD.

443

:

So he stopped taking his Vyvanse.

444

:

He stopped needing to take Xanax at

night 'cause he was so much less anxious

445

:

and he went back and he is working it's

now two and a half, three years out.

446

:

I communicate with him every six months.

447

:

He continues to do fantastic

and he doesn't need a stimulant.

448

:

Yeah, that's fantastic.

449

:

That must be so rewarding to be able to

help folks like that, who've just had

450

:

so much frustration with other options.

451

:

That is one of my core values, is

I wanna bring hope to patients.

452

:

They're told all the time, oh,

there's nothing you can do about it.

453

:

And that frustrates me.

454

:

Yeah I think I'm wondering, just

in terms of what any clinicians who

455

:

are listening might be able to start

doing in their daily practice to

456

:

start thinking more about this and

incorporating some of these ideas.

457

:

Are there some basic blood tests?

458

:

I guess it's difficult to say

specifically, but in general, are

459

:

there, is there a basic approach to

the workup for becoming more suspicious

460

:

about a neuroinflammatory kind of

contribution to mental illness?

461

:

Yeah, there is.

462

:

There is and I'm happy to share it.

463

:

And in fact, if there's a clinician

out there who wants help with,

464

:

getting started doing this treatment,

'cause I don't own this is.

465

:

Dr.

466

:

Lerner's work.

467

:

I'm just championing it.

468

:

So I'm happy to be a consultant

for people who need that.

469

:

So basically, I look at antibody

titers for the herpes viruses.

470

:

So I, I check herpes one two

just because I like that metric.

471

:

And herpes one is

important in Alzheimer's.

472

:

Herpes three is varicella, and

that's, again, it's a good kind of.

473

:

Landmark 'cause most people

have had varicella and therefore

474

:

they'll have antibodies.

475

:

And what you'll find is their

antibody levels are really low.

476

:

If they've.

477

:

If they have active Epstein-Barr virus,

their antibody levels will be very high.

478

:

So for Epstein-Barr, there's a viral coat

antigen and there's a nuclear antigen.

479

:

And then there's also what's called

the early antigen, and that's the

480

:

piece of the protein coat that goes

in and takes over the DNA machinery.

481

:

So it's important to look at that.

482

:

I check herpes five 'cause it's, I

see that as a very small fragment

483

:

of my chronic fatigue patients.

484

:

So cytomegalovirus.

485

:

And then herpes six.

486

:

The rest they get more expensive

'cause they're uncommon.

487

:

So seven and eight are genetic variants

of herpes six and 9, 10, 11, 12

488

:

are only known from brain biopsies.

489

:

So I often offer my patients,

Hey, I'm happy to go get my drill.

490

:

They generally turn me down as rest of

the rest of the lab workup a, C, B, C.

491

:

So then, and then you do a

lymphocyte subset pro profile.

492

:

That allows you to look at

the natural killer cells and

493

:

CD four and CD eight cells.

494

:

If they can afford it a cytokine

panel but generally they cannot.

495

:

So then just do a TGF beta.

496

:

It's much less expensive and it's

the best marker right now for

497

:

lung, for chronic fatigue syndrome

and pretty good for long COVID.

498

:

I also do a C-reactive protein.

499

:

And then I check a creatinine and a liver

function because I'm gonna be putting them

500

:

on a antiviral, which rarely, and let me

emphasize, rarely, like twice in my career

501

:

has anybody had any kinda liver problems

from the antivirals that I'm using.

502

:

Yeah.

503

:

No, that's fantastic.

504

:

Really appreciate that.

505

:

Yeah.

506

:

Just for viewers and listeners,

I'm gonna put links to Dr.

507

:

Henderson's content and contact

information in his clinic and the

508

:

book as well in the show notes.

509

:

So I'd really encourage

people to check that out.

510

:

Maybe just since we but I

referred to your book right there.

511

:

Maybe you can tell us a little bit

about that and the story behind

512

:

the book and what you're hoping

to accomplish by writing that.

513

:

And the book evolved as I wrote it.

514

:

You rewrite books like five or six times.

515

:

And what it came to be was my attempt

to help people rethink depression.

516

:

And so I use Ketamine as a model,

but it's not just about ketamine.

517

:

But I think the way that

Ketamine is administered at

518

:

least in the US is BA wards.

519

:

The standard protocol is six

infusions in two weeks, and

520

:

where that protocol came from.

521

:

So it, it basically came from the

early studies and I actually asked

522

:

one of the investigators in one of

the early studies why they did six

523

:

infusions in two weeks, and his response

was quite literally, I don't know,

524

:

it sounded good that's the science.

525

:

So there is no justification for it.

526

:

In fact, there's a counter.

527

:

Justification for doing six infusions in

two weeks, and that is neuroplasticity.

528

:

You're not gonna make neuroplasticity

happen any faster by having somebody

529

:

get an infusion every other day.

530

:

In fact, in my clinic, I never do

infusions more than once a week, and now

531

:

most of the time it's every two weeks.

532

:

And so by giving neuroplasticity

time to work, my patients get

533

:

better with four infusions.

534

:

So it's, and my response rate

is a 78% response rate, and

535

:

the national average is 51 52.

536

:

So by giving time people spend

less money, get less ketamine

537

:

and have a better outcome.

538

:

I kept telling that story and I kept

telling horror stories of how other

539

:

ketamine clinics had given people giant

doses and then left them in the hallway.

540

:

And I said, I need to just

write the book because I keep

541

:

saying the same thing to people.

542

:

And so that was where the book originally

came from, is I kept finding myself

543

:

explaining the same thing over and over.

544

:

But I think the book, most

importantly, the book gives hope.

545

:

There's lots of stories of patients

and even patients who failed

546

:

to get better with ketamine.

547

:

And that's what leads me to help

people understand there's more to

548

:

depression than just chemical imbalance.

549

:

Yeah.

550

:

Fantastic.

551

:

Yeah, I really appreciate that.

552

:

I appreciate the message of hope

because it is we've been saying a few

553

:

times today already that historically

there's just such a frustration, I

554

:

think, with clinicians and patients.

555

:

And patients are often left

feeling hopeless because after

556

:

years, maybe even decades of.

557

:

Or partially effective treatments,

they still have suffering, they

558

:

still have functional impairments.

559

:

So hopefully with all these other

kinds of options and people can

560

:

continue to just try to maintain hope

that they'll find something, some

561

:

combination of treatments that ends

up working better for yeah, exactly.

562

:

So yeah.

563

:

Based on that and your experience

with all these innovative

564

:

therapies, what would you say is.

565

:

Perhaps the one of the biggest or

a couple of the biggest potential

566

:

opportunities for improvements and

positive changes in mental health

567

:

care over the next five to 10 years.

568

:

Certainly one is the adoption

of infrared photobiomodulation,

569

:

particularly if they're using a multi

watt protocol such as what we do.

570

:

I think that will, would revolutionize

brain health across the spectrum.

571

:

One of the things we haven't talked

about is certain waveless lakes of

572

:

infrared light actually speed the

clearance of toxins from the brain.

573

:

So you want less amyloid in your brain.

574

:

You'll want less alcohol

induced toxins in your brain.

575

:

You want less age related

toxins in your brain.

576

:

Infrared light.

577

:

The other is this

revolution that's happening.

578

:

The next generation of transcranial

magnetic stimulation devices

579

:

have emerged and these devices

have much more powerful magnets.

580

:

They're close to, literally an MRI.

581

:

In terms of their magnetic field.

582

:

And it, number one, speeds the treatment.

583

:

So treatment is reduced from 40

hour long treatments every day of

584

:

the week down to six treatments

lasting 20 some odd minutes.

585

:

So that revolution and TMS interestingly,

TMS turns on neuroplasticity.

586

:

And activates BDNF by

yet a third mechanism.

587

:

So what we're exploring now in

the clinic, and I'm super excited

588

:

about, is the synergy that could

occur between infrared light and

589

:

transcranial magnetic stimulation

in particular areas of the brain.

590

:

Yeah, know.

591

:

That's amazing.

592

:

So it's really interesting to think

about you can all these synergistic start

593

:

to add up, exactly as you're saying.

594

:

You combine that perhaps even with

ketamine and then just even the positive

595

:

therapeutic relationship and that's it's

in some ways, it's really not surprising

596

:

that you're getting such excellent

results, so congratulations for that.

597

:

Thank you.

598

:

Thank you.

599

:

Yeah.

600

:

That's great.

601

:

So I guess I'm curious, 'cause you have

mentioned some of your research endeavors

602

:

what would be, some future ideas or

some hopes plans for collaboration or

603

:

research projects over the next few years?

604

:

Great question.

605

:

Very timely too.

606

:

I've had a long relationship with

Harvard and we're a group of scientists.

607

:

There are under Paula Cassano

and I are working on a grant.

608

:

And this is looking at comparing

the low power infrared light, the

609

:

LEDs that you can buy and stick

on your head at home versus the

610

:

multi watt protocol with controls.

611

:

And the grant that we're preparing

to submit is going to the va.

612

:

So it'd be looking at traumatic

brain injury in veterans.

613

:

And, the veteran population

is so important and un

614

:

underappreciated, at least in the us.

615

:

And every day, the same number

of veterans could die by suicide.

616

:

In 2025, as was true in 2017 no

progress has been made for them.

617

:

And so when I look at, the power

of ketamine, the power of multi

618

:

wat infrared light, and the

power of these next generation

619

:

transcranial magnetic stimulation

devices such as the Exide to help.

620

:

It's just mind boggling to me why we're

not treating veterans aggressively

621

:

with these type of modalities rather

than pills and, group therapy.

622

:

Yeah.

623

:

Particularly the traumatic brain

injury or the PTSD kinds of issues

624

:

that are so common in veterans.

625

:

Yeah.

626

:

Yeah, exactly.

627

:

Yeah.

628

:

For sure.

629

:

I really appreciate it.

630

:

Before we wrap up, is there anything

else that you wanted to bring up Dr.

631

:

Anderson?

632

:

The only thing I would say is that, this.

633

:

I've got one clinic in Denver.

634

:

This should be all over the country.

635

:

So if any listeners out there

are interested in investing

636

:

in, the next generation in

healthcare give me a ring and.

637

:

I'm happy to talk about it.

638

:

A research study such as looking

at PTSD or looking at Parkinson's

639

:

or looking at Alzheimer's,

costs about three, $4 million.

640

:

And the grants are difficult

to get because, we're not.

641

:

University.

642

:

And moving forward moving the field

forward is a slow, laborious process.

643

:

The PO potential for helping

people across North America.

644

:

I'd be happy to have a clinic

in Canada and we've explored

645

:

that with my colleagues.

646

:

It will also take capital.

647

:

Yep.

648

:

Definitely.

649

:

Kudos for all your efforts, and

again, I'm just it's so exciting

650

:

and heartwarming to hear about

all the folks that you're helping.

651

:

So thanks again for a great discussion.

652

:

Absolutely.

653

:

And yeah, I just wish you all the

best and maybe we can have a coffee

654

:

sometime in an upcoming conference.

655

:

That'd be great.

656

:

Excellent.

657

:

Okay.

658

:

That's great.

659

:

So that was our conversation with Dr.

660

:

Theodore Henderson, who's pushing

the boundaries of what's possible

661

:

in psychiatry and mental healthcare

with evidence and empathy.

662

:

If you are curious about treatment

options like infrared laser if you're

663

:

curious about how neuroinflammation is

implicated in various disorders like

664

:

depression, chronic fatigue, long COVID.

665

:

Or if you're curious about how the future

of mental health treatment may well

666

:

involve light instead of just pills.

667

:

His work is really essential

reading, and I'd encourage all of

668

:

the original listeners to check

out his book Brighter Days Ahead.

669

:

Again, I'm gonna put links

to where you can find Dr.

670

:

Henderson's content in the show notes.

671

:

Once again, Dr.

672

:

Henderson, thanks so much for joining

us and just wish you all the best.

673

:

Thank you so much for having me.

674

:

My pleasure.

675

:

Okay, have a great day.

676

:

See you later.

677

:

Thank you.

678

:

Bye-bye.

Show artwork for The Neurostimulation Podcast

About the Podcast

The Neurostimulation Podcast
Exploring the frontier of interventional mental health.
Welcome to The Neurostimulation Podcast — a deep dive into the expanding frontier of interventional mental health.

Hosted by Dr. Michael Passmore, a psychiatrist specializing in neurostimulation and geriatric mental health, this show explores how cutting-edge interventions — from non-invasive brain stimulation (TMS, tDCS, and beyond) to ketamine-assisted psychotherapy — are reshaping the landscape of modern psychiatry and neuroscience.

Each episode bridges science, clinical experience, and human insight, featuring thought leaders and innovators who are redefining how we understand and treat the mind.

Whether you’re a clinician, researcher, student, or simply fascinated by the brain, you’ll discover practical knowledge, fresh ideas, and inspiring conversations that illuminate the evolving art and science of mental health care.

Subscribe for episodes that stimulate your mind, deepen your understanding, and connect you to the future of brain-based healing.

podscan_YIPb4jA8fBJ5ino2RSuBo3BdjrOmPM6c

About your host

Profile picture for Michael Passmore

Michael Passmore

Dr. Michael Passmore is a psychiatrist based in Vancouver, BC, with expertise in non-invasive neurostimulation therapies, geriatric mental health and ketamine-assisted psychotherapy. Having completed specialized training in multiple neurostimulation modalities, including electroconvulsive therapy at Duke University and transcranial magnetic stimulation at Harvard University, Dr. Passmore brings a robust clinical and academic background to his practice. Formerly the head of the neurostimulation program in the department of Psychiatry at Providence Health Care, Dr. Passmore now serves as a clinical associate professor at the University of British Columbia’s Department of Psychiatry. At Sea to Sky NeuroClinic (seatoskyneuro.clinic), Dr. Passmore offers interventional mental health treatments tailored to clients across Canada.​